Norwegian University of Science and Technology (NTNU)

Trondheim, Norway

Department of Cancer Research and Molecular Medicine

link: http://www.ntnu.edu/dmf/ikm


Robin Mjelle MSc PhD
Prof Pål Sætrom PhD
Prof Frank Skorpen PhD
Lars Hagen, PhD
Animesh Sharma, MD PhD
Charalampis Giannadakis MD

Department of Cancer Research and Molecular Medicine aims at carrying out high quality research, supervision and teaching for better health. The department has a central role in teaching and supervision of medical students, as well as master- and ph.d-students in molecular medicine. The activities comprise basic- and clinical research within oncology and mechanisms of cancer development, palliative medicine, haematology, dermatology & venerology, infectious disease, molecular cell biology, physiology, immunology, toxicology, gastroenterology and gastrosurgery, experimental surgery, endocrinology, nephrology, urology and medical ethics. There are several cutting-edge high-through-put core facilities in our department that are used in this project, the Bioinformatics Core Facility (http://www.ntnu.edu/dmf/biocore), the Genomics Core Facility (http://www.ntnu.edu/dmf/gcf) and the Proteomics and Metabolomics Core Facility (http://www.ntnu.edu/dmf/promec).

MR Cancer Group

link: http://www.ntnu.edu/isb/mr-cancer


Trygve Andreassen PhD
Prof Tone F Bathen PhD

The MR Cancer Group at NTNU, headed by Professor Tone F. Bathen, focuses on the use of magnetic resonance imaging (MRI) and spectroscopy in identification of the functional and metabolic changes that precede anatomic evidence of cancer disease.

The group, which was founded by Professor Ingrid S. Gribbestad, is internationally recognized as one of the most experienced in large-scale tissue analyses and has long experience with functional MR imaging in cancer diagnostics.

Our long-term objective is to improve and individualize cancer treatment by developing integrated MR methods and data analysis tools for functional and molecular assessment of tumors.

We use a broad spectrum of systems for cancer studies, spanning from cultured cancer cells to humans, and have access to dedicated MR equipment for in vitro, ex vivo, preclinical and clinical research.